AUPH - Latest News

Aurinia Pharmaceuticals Inc. (AUPH), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.99B. Trailing twelve-month P/E ratio is 6.41. Beta to the broader market is 1.40.

The article list below shows the most recent AUPH headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent AUPH Headlines

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

seekingalpha.com - Aug 12, 2026

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lu

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

zacks.com - Aug 6, 2026

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0. 28 per share, beating the Zacks Consensus Estimate of $0.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

businesswire.com - Aug 6, 2026

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 20

Playing The Biotech Breakout With Insiders

seekingalpha.com - Jul 23, 2026

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

gurufocus.com - Jul 6, 2026

Aurinia Pharmaceuticals Inc.

How News Affects AUPH Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AUPH's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked AUPH news questions

What is the latest AUPH news headline?

The most recent AUPH headline (Aug 12, 2026) is "Aurinia Pharmaceuticals Doubles Down On Its Pipeline". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the AUPH news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What AUPH news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual AUPH options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.